Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This is a two-arm Phase 1b feasibility trial consisting of 20 patients receiving the combination of ipilimumab+nivolumab, either adjuvant, or split neo-adjuvant and adjuvant.
Epistemonikos ID: 7710b59e43b5528d1435fa6104d7275ea3e08bba
First added on: May 12, 2024